Providing affordable access to new treatment for Leukaemia and Lymphoma
More than 920 Australians each year will benefit from affordable access to a new medicine for leukaemia and lymphoma patients. Ibrutinib (sold as Imbruvica®) would normally cost $187,390 on average per course of treatment, putting it beyond the reach of … read more